Integragen Financials
| ALINT Stock | EUR 0.44 0.01 2.22% |
Integragen |
Understanding current and past Integragen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Integragen's financial statements are interrelated, with each one affecting the others. For example, an increase in Integragen's assets may result in an increase in income on the income statement.
Integragen Stock Summary
Integragen competes with Biomerieux, Eurofins Scientific, Sartorius Stedim, and SEB SA. IntegraGen SA provides human genome analysis services for academic and private laboratories in France and the United States. IntegraGen SA was founded in 2000 and is headquartered in vry, France. INTEGRAGEN operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 43 people.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0010908723 |
| Business Address | Genopole Campus 1 |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | integragen.com |
| Phone | 33 1 60 91 09 00 |
| Currency | EUR - Euro |
You should never invest in Integragen without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Integragen Stock, because this is throwing your money away. Analyzing the key information contained in Integragen's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Integragen Key Financial Ratios
Integragen's financial ratios allow both analysts and investors to convert raw data from Integragen's financial statements into concise, actionable information that can be used to evaluate the performance of Integragen over time and compare it to other companies across industries.Integragen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Integragen's current stock value. Our valuation model uses many indicators to compare Integragen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integragen competition to find correlations between indicators driving Integragen's intrinsic value. More Info.Integragen is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.10 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Integragen is roughly 10.05 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Integragen's earnings, one of the primary drivers of an investment's value.Integragen Systematic Risk
Integragen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Integragen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Integragen correlated with the market. If Beta is less than 0 Integragen generally moves in the opposite direction as compared to the market. If Integragen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Integragen is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Integragen is generally in the same direction as the market. If Beta > 1 Integragen moves generally in the same direction as, but more than the movement of the benchmark.
Integragen November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Integragen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Integragen. We use our internally-developed statistical techniques to arrive at the intrinsic value of Integragen based on widely used predictive technical indicators. In general, we focus on analyzing Integragen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Integragen's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 29.58 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 8.51 |
Additional Tools for Integragen Stock Analysis
When running Integragen's price analysis, check to measure Integragen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integragen is operating at the current time. Most of Integragen's value examination focuses on studying past and present price action to predict the probability of Integragen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integragen's price. Additionally, you may evaluate how the addition of Integragen to your portfolios can decrease your overall portfolio volatility.